1324759--3/31/2010--Cereplast_Inc

related topics
{customer, product, revenue}
{product, liability, claim}
{property, intellectual, protect}
{stock, price, share}
{stock, price, operating}
{regulation, government, change}
{condition, economic, financial}
{product, market, service}
{operation, natural, condition}
{personnel, key, retain}
{acquisition, growth, future}
{cost, regulation, environmental}
{regulation, change, law}
The commercial success of our business depends on the widespread market acceptance of products manufactured with our bio-based resins. We have only recently commenced industrial scale production of our bio-based resins and it is possible that some of our bio-based resins or plastic products made with our bio-based resins may not perform as well as other resins or traditional plastics. We may not be successful in protecting our intellectual property and proprietary rights and may be required to expend significant amounts of money and time in attempting to protect these rights. If we are unable to protect our intellectual property and proprietary rights, our competitive position in the market could suffer. Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information. Management and affiliates own enough shares to have a substantial impact on shareholder vote which could cause us to take action that may not be in the best interest of all shareholders. Given our limited resources, we may not effectively manage our growth. Established product manufacturers could improve the ability to recycle their existing products or develop new environmentally preferable products which could render our technology less competitive. Many potential competitors who have greater resources and experience than we do may develop products and technologies that compete with ours. We rely on prime grade polylactic acid ( PLA ) supplied from NatureWorks, LLC in manufacturing some of our Compostables resins. If we lose NatureWorks, LLC as a supplier, the price of these resins may increase or the introduction and market acceptance of these resins may be delayed and our results of operations could be materially adversely affected. Fluctuations in the costs of our raw materials and competitive products could have an adverse effect on our results of operations and financial condition. During the year ended December 31, 2009, we had three significant customers that accounted for 54.4% of total sales. The loss of these customers could adversely affect our short-term sales and profitability. Our operations are subject to regulation by the U.S. Food and Drug Administration. Regulatory changes applicable to us, or the products in our end-use markets, could adversely affect our financial condition and results of operations. We may be liable for damages based on product liability claims brought against our customers in our end-use markets. Loss of key personnel or our inability to attract and retain new qualified personnel could hurt our business and inhibit our ability to operate and grow successfully. Disruptions of continuous operation of our new Seymour bioplastic production facility could materially and adversely affect our results of operations. Downturns in general economic conditions could adversely affect our profitability. Risks related to our stock Our common stock is subject to the Penny Stock rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.

Full 10-K form ▸

related documents
1025573--4/2/2007--NATROL_INC
18937--2/26/2008--CERADYNE_INC
1409565--9/25/2009--Puramed_Bioscience_Inc.
780127--1/12/2007--SYNOVIS_LIFE_TECHNOLOGIES__INC
1013606--2/29/2008--ENDOLOGIX_INC_/DE/
1050007--11/30/2006--NUTRACEUTICAL_INTERNATIONAL_CORP
949874--3/14/2006--YOUNG_INNOVATIONS_INC
949874--3/12/2009--YOUNG_INNOVATIONS_INC
949874--3/15/2007--YOUNG_INNOVATIONS_INC
949874--3/14/2008--YOUNG_INNOVATIONS_INC
8146--4/13/2009--ASTRO_MED_INC_/NEW/
1311538--6/29/2009--Castle_Brands_Inc
18937--3/16/2006--CERADYNE_INC
1033905--3/16/2006--LUMINEX_CORP
70793--12/11/2006--NBTY_INC
744962--9/29/2008--NUTRITION_21_INC
1006195--3/15/2007--MATRIXX_INITIATIVES_INC
31791--3/1/2010--PERKINELMER_INC
1006195--6/8/2009--MATRIXX_INITIATIVES_INC
882873--9/13/2006--UROLOGIX_INC
70793--11/27/2007--NBTY_INC
943894--3/31/2010--EZENIA_INC
5768--6/15/2009--AMERICAN_SCIENCE_&_ENGINEERING_INC
1011060--6/27/2007--CARDIOTECH_INTERNATIONAL_INC
1011060--6/28/2006--CARDIOTECH_INTERNATIONAL_INC
874716--2/27/2008--IDEXX_LABORATORIES_INC_/DE
5768--6/13/2007--AMERICAN_SCIENCE_&_ENGINEERING_INC
5768--6/13/2008--AMERICAN_SCIENCE_&_ENGINEERING_INC
57725--9/29/2008--LANNETT_CO_INC
882873--9/21/2009--UROLOGIX_INC